Pharmacokinetics and Safety of a Novel Clofazimine Formulation and Dosing Strategy in Children With Rifampicin-resistant Tuberculosis

Clicks: 28
ID: 324980
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #347 of 508 articles by views in The Journal of infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 508 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Clofazimine is commonly included in multidrug regimens for children with multidrug-resistant and rifampicin-resistant tuberculosis (MDR/RR-TB), but accurate pediatric dosing has been limited by 100-mg soft-gel capsules that cannot be reliably divided. We evaluated the exposure and safety of a novel 50-mg clofazimine tablet using revised once-daily weight-banded dosing informed by a previous study (Clofazimine PK1). Methods Children <18 years weighing <30 kg receiving MDR/RR-TB treatment, including clofazimine, were enrolled. Sparse and semi-intensive pharmacokinetic sampling was completed at baseline and at weeks 2 and 12. Model-predicted weekly steady-state area-under-the-curve (wAUCss) was compared with an adult target of 111.79 mg·h/L. Safety monitoring included clinical, laboratory, and electrocardiogram (ECG) monitoring. Results Twelve children were included (median age 2.8 years; range 0.6–8.2). Median predicted wAUCss was 106 mg·h/L (range 76.9–274), within 25% of target. Two grade 3 adverse events (drug-induced liver injury and skin hyperpigmentation) possibly related to clofazimine, but no other clofazimine-related serious adverse events, were observed, The Fridericia corrected QT (QTcF) interval typically increased with 0.042 ms per1-µg/L increase in clofazimine concentration; five QTcF prolongations (>460–480 ms) occurred in three participants. Conclusions The revised once-daily dosing with the 50-mg clofazimine tablet achieved the predefined exposure target. Clinically important adverse events support cautious use with ECG and laboratory monitoring and further evaluation before broad adoption. Clinical Trials Registration South African National Clinical Trials Register (https://sanctr.samrc.ac.za/; DOH-27-0620-6415).
Reference Key
openalex_W7202394624 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Elri Nortier, Milena M Boczar, Jennifer Hughes, Joh-Nell van der Westhuizen, Megan Palmer, Anthony J. Garcia‐Prats, Louvina E. van der Laan, James C. Nielsen, Mats O. Karlsson, Adelaide Carelse, Ingrid Courtney, Heather Draper, H. Simon Schaaf, Alan Faraj, Elin M. Svensson, Anneke C. Hesseling
Are you one of these authors? Claim your profile
Journal The Journal of infectious diseases
Year 2026
DOI
10.1093/infdis/jiag381
URL
https://doi.org/10.1093/infdis/jiag381
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.